A Phase 2 clinical trial testing Galápagos‘ experimental oral therapy GLPG3667 in people with systemic lupus erythematosus (SLE) has failed to meet its main goal, although some promising trends were observed in secondary measures, Galápagos announced. The Phase 2 trial, dubbed GALACELA (NCT05856448), tested two doses of GLPG3667…
Discussion
Holidays are either the best or the absolute worst time to get out and travel. Yes, there’s the joy of seeing extended family, sharing gifts, laughing through photo albums, reuniting with old friends over homemade eggnog and caroling, and making new memories. But then, like clockwork, concerns arise about…
Lupus is an autoimmune inflammatory disease that can affect multiple systems in the body.
While the cause of lupus is often unknown, it is possibly due to a combination of genetics and the environment.
Lupus affects people in different ways, and symptoms vary among patients. Symptoms come and go during periods called flares.
